Indian Diabetes Market

Regular Price: USD 4,950

Special Price USD 4,208

15% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 4,208

PAY BY INVOICE

Be the first to review this product

This research service studies the Indian Diabetes market. It provides the number of Type 1 and Type 2 diabetic patients in India across different age groups and forecasts these numbers up to 2030. It provides a detailed analysis of the two major segments of the market, the insulin market segment and the anti-diabetic medications segment, which includes oral anti-diabetics as well as injectable ones. Drivers and Restraints faced by the participants in this market have been analysed. Based on these, a quantitative analysis and revenue forecast from 2011 up to 2017 has been provided for the total market as well as the two segments: Insulin and Anti-diabetic medications. Finally, strategic recommendations have also been provided.

Table of Contents

Executive SummaryExecutive SummaryExecutive Summary (continued)Executive Summary—Market Engineering MeasurementsExecutive Summary—Market Engineering Measurements (continued)Executive Summary—CEO’s PerspectiveMarket OverviewMarket Overview—DefinitionsMarket Overview—Definitions (continued)Market Overview—Definitions (continued)Market Overview—Definitions (continued)Diabetes Overview—GlobalWorldwide Diabetes OverviewMarket Overview—Key Questions This Study Will AnswerMarket Overview—Segmentation Market Overview—Patient Share Forecast by Treatment TypeMarket Overview—Patient Share Forecast by Treatment Type (continued)Total Diabetes Market: Key Treatment Challenges in India (2011)Distribution ChannelsSoutheast Asia Diabetes OverviewSoutheast Asia Diabetes Overview (continued)External Challenges: Drivers and Restraints—Total Diabetes MarketDrivers and RestraintsDrivers ExplainedDrivers Explained (continued)Drivers Explained (continued)Drivers Explained (continued)Drivers Explained (continued)Restraints ExplainedRestraints Explained (continued)Restraints Explained (continued)Restraints Explained (continued)Restraints Explained (continued)Forecasts and Trends—Total Diabetes MarketMarket Engineering MeasurementsForecast AssumptionsTotal Diabetes Market—Revenue ForecastRevenue Forecast DiscussionTotal Diabetes Market—Per cent Revenue Forecast by SegmentPer cent Revenue Forecast by Segment DiscussionDemand Analysis—Total Diabetes MarketDiabetes Population Overview—India Diabetes Population Overview—India (continued)Diabetes Population Overview—India (continued)Patient Share ForecastsMarket PotentialCompanies by Product SegmentMarket Share and Competitive Analysis—Total Diabetes MarketCompetitive Analysis—Market ShareMarket Share AnalysisCompetitive EnvironmentInsulin Segment BreakdownInsulin Segment BreakdownInsulin Segment—Market Engineering MeasurementsInsulin Segment—Revenue ForecastInsulin Segment—Revenue Forecast DiscussionCompetitive Analysis—Segment ShareCompetitive Analysis—Segment ShareCompetitive EnvironmentInsulin Versus Insulin AnaloguesInsulin Versus Insulin Analogues (continued)R&D PipelineR&D Pipeline (continued)Intermediate-Acting Insulin Sub-Segment BreakdownIntermediate-Acting Insulin—Market Engineering MeasurementsIntermediate-Acting Insulin—Competitive AnalysisFast-Acting Insulin Sub-Segment BreakdownFast-Acting Insulin—Market Engineering MeasurementsFast-Acting Insulin—Competitive AnalysisLong-Acting Insulin Sub-Segment BreakdownLong-Acting Insulin—Market Engineering MeasurementsLong-Acting Insulin—Competitive AnalysisPre-Mixed Insulin Sub-Segment BreakdownPre-Mixed Insulin—Market Engineering MeasurementsPre-Mixed Insulin—Competitive AnalysisAnimal Insulin Sub-Segment BreakdownAnimal Insulin—Market Engineering MeasurementsAnimal Insulin—Competitive AnalysisInsulin DeliveryInsulin DeliveryInsulin Delivery (continued)Insulin Delivery (continued)Anti–Diabetics Medications Segment BreakdownAnti-Diabetics Medications Segment BreakdownAnti-Diabetes Medications Segment—Market Engineering MeasurementsAnti-Diabetes Medications Segment—Revenue ForecastRevenue Forecast DiscussionCompetitive Analysis—Segment ShareCompetitive Analysis—Segment Share (continued)Competitive EnvironmentBiguanides (metformin) Sub-Segment BreakdownBiguanides (metformin)Biguanides (metformin)—Market Engineering MeasurementsBiguanides (metformin)Sulfonylureas Sub-Segment BreakdownSulfonylureas Glimepiride—Market Engineering MeasurementsGlimepirideGlibenclamide—Market Engineering MeasurementsGlibenclamide Gliclazide—Market Engineering MeasurementsGliclazideGlipizide—Market Engineering MeasurementsGlipizideAlpha-Glucosidase Inhibitors Sub-Segment BreakdownAlpha-Glucosidase InhibitorsVoglibose—Market Engineering MeasurementsVoglibose—Product PortfolioAcarbose—Market Engineering MeasurementsAcarbose—Product PortfolioThiazolidinediones Sub-Segment BreakdownThiazolidinedionesRosiglitazone Banned in IndiaPioglitazone—Market Engineering MeasurementsPioglitazone—Product PortfolioMeglitinides Sub-Segment BreakdownMeglitinidesRepaglinide—Market Engineering MeasurementsRepaglinide—Product PortfolioNateglinide—Market Engineering Measurements Nateglinide—Product PortfolioDPP-IV Inhibitors Sub-Segment BreakdownDPP-IV InhibitorsSitagliptin—Market Engineering MeasurementsSitagliptin—Product PortfolioVildagliptin—Market Engineering MeasurementsVildagliptin—Product PortfolioSaxagliptin—Market Engineering MeasurementsSaxagliptin—Product PortfolioLinagliptin—Market Engineering MeasurementsLinagliptin—Product PortfolioGlucagon-like Peptides -1 (GLP-1s) Sub-Segment BreakdownExenatide—Market Engineering MeasurementsExenatide—Product PortfolioLiraglutide—Market Engineering MeasurementsLiraglutide—Product PortfolioFixed-Dose Combination Sub-Segment BreakdownFixed-Dose CombinationFixed-Dose Combination (continued)Fixed-Dose Combination (continued)Fixed-Dose Combination (continued)Fixed-Dose Combination (continued)Glimepiride + metforminGlimepiride + metforminGlimepiride + metformin—Market Engineering MeasurementsGlimepiride + metformin—Product PortfolioSitagliptin + metforminSitagliptin + metforminSitagliptin + metformin—Market Engineering MeasurementsSitagliptin + metformin—Product PortfolioGlipizide + metforminGlipizide + metforminGlipizide + metformin—Market Engineering MeasurementsGlipizide + metformin—Product PortfolioGliclazide + metforminGliclazide + metforminGliclazide + metformin—Market Engineering MeasurementsGliclazide + metformin—Product PortfolioGlibenclamide + metforminGlibenclamide + metforminGlibenclamide + metformin—Market Engineering MeasurementsGlibenclamide + metformin—Product PortfolioVildagliptin + metforminVildagliptin + metforminVildagliptin + metformin—Market Engineering MeasurementsVildagliptin + metformin—Product PortfolioPioglitazone + metforminPioglitazone + metforminPioglitazone + Metformin—Market Engineering MeasurementsPioglitazone + metformin—Product PortfolioPioglitazone + GlimepiridePioglitazone + GlimepiridePioglitazone + Glimepiride—Market Engineering MeasurementsPioglitazone + Glimepride—Product PortfolioMetformin + VogliboseMetformin + VogliboseMetformin + Voglibose—Market Engineering MeasurementsMetformin + Voglibose—Product PortfolioPioglitazone + metformin + GlimepiridePioglitazone + metformin + GlimepiridePioglitazone + metformin + Glimepiride—Market Engineering MeasurementsPioglitazone + metformin + Glimepiride—Product PortfolioFuture Trends in Diabetes ManagementFuture Trends in Diabetes ManagementFuture Trends in Diabetes Management (continued)Company ProfilesNovo Nordisk Sanofi AventisEli LillyBioconNovartisUSV LupinMSD (Merck Sharp & Dohme) Intas PharmaDr Reddy’sStrategic RecommendationsStrategic RecommendationsStrategic Recommendations (continued)Strategic Recommendations (continued)Strategic Recommendations (continued)Strategic Recommendations (continued)The Last WordThe Last Word—Three Big PredictionsThe Last Word—DiscussionLegal DisclaimerAppendixMarket Engineering MethodologyLearn More—Next Steps




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 06-Nov-17

Region : South Asia, Middle East & North Africa

Release Date : 11-Dec-15

Region : South Asia, Middle East & North Africa

Release Date : 09-Apr-2015

Region : South Asia, Middle East & North Africa

Release Date : 5-Jul-13

Region : South Asia, Middle East & North Africa

Release Date : 23-Jan-2013

Region : South Asia, Middle East & North Africa

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.